Velcade bortezomib: Phase IIIb data

The open-label, U.S. Phase IIIb UPFRONT trial in 300 newly diagnosed MM patients showed that induction therapy with Velcade plus dexamethasone (VcD), Velcade plus thalidomide and dexamethasone (VcTD), or Velcade plus melphalan and prednisone (VcMP) for 24 weeks produced ORRs of 68%, 78% and 71%, respectively. Rates of CR/nCR were 24%, 36% and 31% for the VcD, VcTD and VcMP arms, respectively, and rates of >=VGPR were 36%, 44% and 40%, respectively. ...